Immunovant, Inc.
IMVT
Rangering i aksjer
#3062
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Aksjekurs
$28.32
Sist synkronisert: 2026-10-21
Markedsverdi
$5.85B
Endring (1 dag)
-0.94%
Endring (1 år)
49.85%
Land
US
Handel Immunovant, Inc. (IMVT)
Kategori
Healthcare
Aksjeprishistorikk for Immunovant, Inc. (IMVT)
Høyeste sluttskurs: $30.02 den 2026-10-01
Laveste sluttskurs: $9.88 den 2019-06-01
Laveste sluttskurs: $9.88 den 2019-06-01
Aksjeprishistorikk for Immunovant, Inc. fra 2019 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | 20.78% |
| 2025 | -7.38% |
| 2024 | -34.45% |
| 2023 | 163.89% |
| 2022 | 99.44% |
| 2021 | -84.02% |
| 2020 | 273.47% |
| 2019 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.21 | 7.77% |
CH
|
